Alan Tan

882 total citations
52 papers, 442 citations indexed

About

Alan Tan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Alan Tan has authored 52 papers receiving a total of 442 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 22 papers in Pulmonary and Respiratory Medicine and 20 papers in Surgery. Recurrent topics in Alan Tan's work include Bladder and Urothelial Cancer Treatments (14 papers), Cancer Genomics and Diagnostics (12 papers) and Renal cell carcinoma treatment (10 papers). Alan Tan is often cited by papers focused on Bladder and Urothelial Cancer Treatments (14 papers), Cancer Genomics and Diagnostics (12 papers) and Renal cell carcinoma treatment (10 papers). Alan Tan collaborates with scholars based in United States, Canada and United Kingdom. Alan Tan's co-authors include Marc B. Hershenson, Limei Zhou, Anning Lin, Kristen Page, Jing Li, Jing Li, Huda Salman, John M. Richart, Vanessa Leone and Sawako Miyoshi and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Alan Tan

42 papers receiving 437 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alan Tan United States 11 122 121 118 77 73 52 442
Zdeňka Navrátilová Czechia 11 130 1.1× 128 1.1× 68 0.6× 110 1.4× 80 1.1× 28 406
Eui‐Young So United States 12 47 0.4× 152 1.3× 96 0.8× 163 2.1× 53 0.7× 17 397
Eleana Harmel-Laws United States 9 68 0.6× 125 1.0× 128 1.1× 130 1.7× 20 0.3× 9 457
Hai-Xing Jiang China 10 48 0.4× 99 0.8× 48 0.4× 101 1.3× 67 0.9× 22 344
Jhung W. Jhung United States 8 80 0.7× 127 1.0× 101 0.9× 158 2.1× 25 0.3× 10 381
Geom-Seog Seo South Korea 10 47 0.4× 100 0.8× 56 0.5× 99 1.3× 16 0.2× 25 363
A. Mazzone Italy 4 43 0.4× 116 1.0× 43 0.4× 109 1.4× 26 0.4× 5 369
Viviane Tricottet France 10 44 0.4× 167 1.4× 55 0.5× 197 2.6× 52 0.7× 17 575
Luke Hatchwell Australia 14 100 0.8× 222 1.8× 36 0.3× 237 3.1× 250 3.4× 14 639
Jerilyn K. Gray United States 14 91 0.7× 278 2.3× 80 0.7× 260 3.4× 47 0.6× 22 628

Countries citing papers authored by Alan Tan

Since Specialization
Citations

This map shows the geographic impact of Alan Tan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Tan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Tan more than expected).

Fields of papers citing papers by Alan Tan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Tan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Tan. The network helps show where Alan Tan may publish in the future.

Co-authorship network of co-authors of Alan Tan

This figure shows the co-authorship network connecting the top 25 collaborators of Alan Tan. A scholar is included among the top collaborators of Alan Tan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan Tan. Alan Tan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Simon, Nicholas I., Stephanie Berg, Alan Tan, et al.. (2025). Preferred treatment regimens for rare genitourinary (GU) malignancies.. Journal of Clinical Oncology. 43(5_suppl). 780–780.
2.
Tan, Alan, Giancarlo Bonora, Binggang Xiang, et al.. (2025). Comprehensive bladder cancer molecular profiling and monitoring based on mutational, epigenomic, and expression data from real-world patients.. Journal of Clinical Oncology. 43(5_suppl). 860–860.
3.
Kim, Hyung L., Catherine M. Tangen, Ulka N. Vaishampayan, et al.. (2024). SWOG S1931 (PROBE): PHASE III RANDOMIZED TRIAL OF IMMUNE CHECKPOINT INHIBITOR (ICI) COMBINATION REGIMEN WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY (CN) IN ADVANCED RENAL CANCER [NCT04510597]. Urologic Oncology Seminars and Original Investigations. 42. S4–S4. 2 indexed citations
4.
Chen, Emily Y., et al.. (2024). Detection of molecular residual disease in stage II and III melanoma utilizing circulating tumor DNA.. Journal of Clinical Oncology. 42(16_suppl). e21564–e21564. 1 indexed citations
5.
6.
7.
Gupta, Shilpa, Karla V. Ballman, Andrea B. Apolo, et al.. (2024). MAIN-CAV: Phase III randomized trial of maintenance cabozantinib (CABO) and avelumab (Av) vs Av after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).. Journal of Clinical Oncology. 42(4_suppl). TPS714–TPS714. 2 indexed citations
8.
9.
Tan, Alan, et al.. (2024). Longitudinal circulating tumor DNA monitoring for detection of molecular residual disease in patients with penile squamous cell carcinoma.. Journal of Clinical Oncology. 42(4_suppl). 11–11. 1 indexed citations
10.
Ritz, Ethan, et al.. (2024). The impact of demographics and socioeconomic status on the receipt of immunotherapy for stage III melanoma. Surgical Oncology. 57. 102156–102156.
11.
12.
Akers, Rachel, et al.. (2023). Melanoma disparities in urban vs rural communities in the era of immunotherapy: An NCDB analysis.. Journal of Clinical Oncology. 41(16_suppl). 9578–9578. 1 indexed citations
13.
Nagar, Himanshu, Karla V. Ballman, Scott T. Tagawa, et al.. (2023). Alliance A032002 (ART): Phase II randomized trial of atezolizumab versus atezolizumab and radiation therapy for platinum-ineligible/refractory metastatic urothelial cancer.. Journal of Clinical Oncology. 41(6_suppl). TPS589–TPS589.
14.
Gupta, Shilpa, Karla V. Ballman, Matt D. Galsky, et al.. (2023). MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).. Journal of Clinical Oncology. 41(16_suppl). TPS4609–TPS4609. 1 indexed citations
15.
Shah, Nina, Miguel‐Angel Perales, Cameron J. Turtle, et al.. (2021). Phase I Study Protocol: NKTR-255 as Monotherapy or Combined with Daratumumab or Rituximab in Hematologic Malignancies. Future Oncology. 17(27). 3549–3560. 17 indexed citations
16.
Tan, Alan. (2013). The accuracy of clinical coding for diverticular disease and the implication for trainees intending to undertake research. International Journal of Surgery. 11(8). 689–689. 1 indexed citations
17.
Zhou, Limei, Alan Tan, & Marc B. Hershenson. (2004). Yersinia YopJ inhibits pro-inflammatory molecule expression in human bronchial epithelial cells. Respiratory Physiology & Neurobiology. 140(1). 89–97. 19 indexed citations
18.
Shimotake, Thomas K., Kandelaria M. Rumilla, Jing Li, et al.. (2004). Interleukin (IL)-1β in Tracheal Aspirates from Premature Infants Induces Airway Epithelial Cell IL-8 Expression via an NF-κB Dependent Pathway. Pediatric Research. 56(6). 907–913. 16 indexed citations
19.
Page, Kristen, et al.. (2003). German cockroach extract increases bronchial epithelial cell interleukin‐8 expression. Clinical & Experimental Allergy. 33(1). 35–42. 58 indexed citations
20.
Funkhouser, Ann W., Alan Tan, Limei Zhou, et al.. (2003). Rhinovirus 16 3C Protease Induces Interleukin-8 and Granulocyte-Macrophage Colony-Stimulating Factor Expression in Human Bronchial Epithelial Cells. Pediatric Research. 55(1). 13–18. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zdeňka Navrátilová Breakdown of academic impact, for papers by Eui‐Young So Breakdown of academic impact, for papers by Eleana Harmel-Laws Breakdown of academic impact, for papers by Hai-Xing Jiang Breakdown of academic impact, for papers by Jhung W. Jhung Breakdown of academic impact, for papers by Geom-Seog Seo Breakdown of academic impact, for papers by A. Mazzone Breakdown of academic impact, for papers by Viviane Tricottet Breakdown of academic impact, for papers by Luke Hatchwell Breakdown of academic impact, for papers by Jerilyn K. Gray
Rankless by CCL
2026